Compare Plby Group Inc (PLBY) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Plby Group Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Plby Group Inc trades at $1 (market cap $118.21M), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 1079× Plby Group Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Plby Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Plby Group Inc for 24 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| PLBY | VRTX | |
|---|---|---|
Market Cap | $118.21M | $127.55B |
Volume | 919,783 | 1,487,944 |
Sector | Consumer Cyclical | Health |
52-Week High | $2.71 | $557.96 |
52-Week Low | $0.99 | $407.37 |
Typical Hold Time | 24 Days | 120 Days |
Enterprise Value | $263.80M | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PLBY Group trades at $1.02, down 1.92% on the day, with a bearish technical signal from moving averages. The company shows improving fundamentals with revenue stabilizing around $120-125 million and net losses narrowing significantly from -$278 million in 2022 to -$13 million in 2025. Recent management appointments aim to drive brand growth, while positive operating cash flow in 2025 and projected profitability in 2026 signal potential turnaround.
While analyst consensus remains strongly bullish (75% buy ratings), the stock faces headwinds from high debt levels and negative shareholder equity. The path to sustainable profitability remains the key catalyst, with current valuation metrics suggesting cautious optimism if execution improves. Near-term price action appears range-bound near support levels.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% on the day, with a bearish technical signal despite a neutral oscillator reading. The company reported strong 2025 revenue of $12.00B and net income of $3.95B, with a net margin of 35%. Recent positive Phase 2b data for its kidney disease drug inaxaplin highlights pipeline expansion beyond cystic fibrosis dominance. Analyst consensus is strongly bullish with an 83.9% buy rating and a $573.50 price target, implying 13.4% upside.
The outlook for VRTX is positive, driven by its profitable core business and promising pipeline, but faces risks from clinical trial outcomes and competitive pressures. The stock's current valuation at a P/E of 29.45 is reasonable given its growth prospects, though investors should monitor execution on new drug approvals and market adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
